We also observed recurrent SVs targeting the tumor suppressor gene DLG2 in 15/29 OS patients38 and 3/29 neuroblastoma, of which 6 had homozygous deletions (Supplementary Table 9). This evidence concerns the gene DLG2 and neuroblastoma.